Increased suicide attempt rate among patients interrupting use of atypical antipsychotics

Pharmacoepidemiology and Drug Safety

Volumn 12, Issue 5, 2003, Pages 423-424

  Herings, Rom M C ^a,b   Erkens, Joëlle A ^a  

^a PHARMO INSTITUTE FOR DRUG OUTCOMES RESEARCH   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Atypical antipsychotic drug; Compliance; Schizophrenia; Suicide attempt

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; OLANZAPINE; RISPERIDONE;

ADOLESCENT; ADULT; ARTICLE; CONTROLLED STUDY; DRUG INTERMITTENT THERAPY; DRUG USE; EPIDEMIOLOGICAL DATA; FOLLOW UP; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MEDICAL RECORD; PATIENT COMPLIANCE; POPULATION RESEARCH; PRIORITY JOURNAL; REGRESSION ANALYSIS; RISK ASSESSMENT; RISK FACTOR; SCHIZOPHRENIA; SUICIDE ATTEMPT;

ADOLESCENT; AGE FACTORS; ANTIPSYCHOTIC AGENTS; HUMANS; KAVA; MIDDLE AGED; NETHERLANDS; PATIENT COMPLIANCE; PSYCHOTIC DISORDERS; RISK FACTORS; SUICIDE; TIME FACTORS;

EID: 0042370349     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/pds.837     Document Type: Article

References (4)

1. Meltzer HY. Suicidality in schizophrenia: A review of the evidence for risk factors and treatment options. Curr Psychiatry Rep 2002; 4(4): 279-283.
2. Gerlach J. Improving outcome in schizophrenia: The potential importance of EPS and neuroleptic dysphoria. Ann Clin Psychiatry 2002; 14(1): 47-57.
3. Schillevoort I, De Boer A, Herings RM, Roos RA, Jansen PA, Leufkens HG. Antipsychotic-induced extrapyramidal syndromes. Risperidone compared with low- and high-potency conventional antipsychotic drugs. Eur J Clin Pharmacol 2001; 57(4): 327-331.
4. De Hert M, McKenzie K, Peuskens J. Risk factors for suicide in young people suffering from schizophrenia: A long-term follow-up study. Schizophr Res 2001; 47(2-3): 127-134.